In addition, the injection of an IL-6 inhibitor (Tocilizumab) showed better embryo development and survivability than that of a TNF-α inhibitor (Infliximab and Etanercept) to inhibit CML-induced inflammation. Here, TNF is linked to chronic myelogenous leukemia, BCR-ABL1 positive.